Value proposition

AI-Driven Drug Discovery to Combat Drug Resistance in Cancer - Member of NVIDIA Inception Program

At Synamics Therapeutics, our innovative strategy is not just about treating cancer—it's about staying one step ahead. The heart of our approach lies in our advanced AI-driven resistance modeling. This allows us to not only confront existing cancer mutations but also to proactively anticipate and target potential future mutations. By predicting these future resistance pathways, our AI model guides the design of our small molecules to effectively combat evolving cancer threats. This forward-thinking approach ensures the sustained efficacy of our therapies, significantly enhancing patient outcomes and leading the way in the evolution of precision oncology.